BR112021014074A2 - Proteínas de ligação ao antígeno anti-receptor il2 gama - Google Patents

Proteínas de ligação ao antígeno anti-receptor il2 gama

Info

Publication number
BR112021014074A2
BR112021014074A2 BR112021014074A BR112021014074A BR112021014074A2 BR 112021014074 A2 BR112021014074 A2 BR 112021014074A2 BR 112021014074 A BR112021014074 A BR 112021014074A BR 112021014074 A BR112021014074 A BR 112021014074A BR 112021014074 A2 BR112021014074 A2 BR 112021014074A2
Authority
BR
Brazil
Prior art keywords
antibodies
binding proteins
gamma receptor
fragments
antigen
Prior art date
Application number
BR112021014074A
Other languages
English (en)
Inventor
J Murphy Andrew
M Orengo Jamie
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112021014074A2 publication Critical patent/BR112021014074A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

proteína de ligação ao antígeno ant-receptor il2 gama. a presente invenção provê anticorpos e fragmentos de ligação ao antígeno (p. ex., anticorpos humanos) que se ligam especifica-mente à subunidade gama do receptor de il2 (il2r) humano. métodos para tratar ou prevenir doenças mediadas pela il2r (p. ex., doença do enxerto contra o hospedeiro) usando os anticorpos e fragmentos são também providos juntamente com métodos para produzir os anticorpos e fragmentos.
BR112021014074A 2019-02-01 2020-01-30 Proteínas de ligação ao antígeno anti-receptor il2 gama BR112021014074A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962799851P 2019-02-01 2019-02-01
PCT/US2020/015841 WO2020160242A1 (en) 2019-02-01 2020-01-30 Anti-il2 receptor gamma antigen-binding proteins

Publications (1)

Publication Number Publication Date
BR112021014074A2 true BR112021014074A2 (pt) 2021-11-23

Family

ID=69740681

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021014074A BR112021014074A2 (pt) 2019-02-01 2020-01-30 Proteínas de ligação ao antígeno anti-receptor il2 gama

Country Status (15)

Country Link
US (2) US11629195B2 (pt)
EP (1) EP3917962A1 (pt)
JP (1) JP2022519068A (pt)
KR (1) KR20210123350A (pt)
CN (1) CN113474370A (pt)
AU (1) AU2020214812A1 (pt)
BR (1) BR112021014074A2 (pt)
CA (1) CA3126117A1 (pt)
CL (1) CL2021002008A1 (pt)
CO (1) CO2021009693A2 (pt)
EA (1) EA202192090A1 (pt)
IL (1) IL284579A (pt)
MX (1) MX2021008958A (pt)
SG (1) SG11202107272SA (pt)
WO (1) WO2020160242A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113474370A (zh) * 2019-02-01 2021-10-01 瑞泽恩制药公司 抗IL2受体γ抗原结合蛋白
EP4139341A1 (en) * 2020-04-21 2023-03-01 Regeneron Pharmaceuticals, Inc. Il-2 variants with reduced binding to il-2 receptor alpha and uses thereof
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
CA3236138A1 (en) * 2021-11-02 2023-05-11 Shiyong GONG Anti-cd122 antibodies, anti-cd132 antibodies, and related bispecific binding proteins
CN114990206B (zh) * 2022-06-02 2023-04-07 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) Common γ-chain受体作为药物靶点在制备治疗狼疮性肾炎药物中的应用
US20240027432A1 (en) 2022-07-13 2024-01-25 Regeneron Pharmaceuticals, Inc. Mild acid immunoassays for detection of analytes
WO2024073606A1 (en) 2022-09-28 2024-04-04 Regeneron Pharmaceuticals, Inc. Antibody resistant modified receptors to enhance cell-based therapies

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US5693489A (en) 1984-03-30 1997-12-02 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
JP3255699B2 (ja) 1992-04-23 2002-02-12 味の素株式会社 ヒトＩＬ−２レセプターγ鎖分子
US6576236B1 (en) 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
WO1997017360A2 (en) 1995-11-09 1997-05-15 Dana-Farber Cancer Institute Methods for modulating t cell responses by manipulating a common cytokine receptor gamma chain
AU2937597A (en) 1996-05-10 1997-12-05 Biogen, Inc. Common gamma chain blocking agents
US6861227B2 (en) 1998-03-19 2005-03-01 Human Genome Sciences, Inc. Antibodies to cytokine receptor common gamma chain like
AU2001247899A1 (en) 2000-04-06 2001-10-23 Genetics Institute, Llc Polynucleotides encoding novel secreted proteins
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2606102C (en) 2005-04-26 2014-09-30 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
CN102939305B (zh) * 2010-04-08 2016-08-17 Jn生物科学有限责任公司 对cd122的抗体
WO2012096994A2 (en) 2011-01-10 2012-07-19 Emory University Antibodies directed against influenza
HRP20230623T1 (hr) 2012-09-12 2023-09-29 Genzyme Corporation Polipeptidi koji sadrže fc domenu s promijenjenom glikozilacijom i smanjenom efektorskom funkcijom
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
ES2763198T3 (es) 2014-07-21 2020-05-27 Delinia Inc Moléculas que selectivamente activan las células T reguladoras para el tratamiento de enfermedades autoinmunes
JP6908591B2 (ja) * 2015-08-06 2021-07-28 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ Ｉｌ２ｒベータ／共通ガンマ鎖抗体
WO2018156649A1 (en) 2017-02-22 2018-08-30 Flagship Pioneering, Inc. Compositions of t cell modulator (tcm) molecules and uses thereof
CN113474370A (zh) * 2019-02-01 2021-10-01 瑞泽恩制药公司 抗IL2受体γ抗原结合蛋白

Also Published As

Publication number Publication date
CO2021009693A2 (es) 2021-08-09
CA3126117A1 (en) 2020-08-06
AU2020214812A1 (en) 2021-09-23
IL284579A (en) 2021-08-31
MX2021008958A (es) 2021-11-04
US20200247894A1 (en) 2020-08-06
EP3917962A1 (en) 2021-12-08
WO2020160242A1 (en) 2020-08-06
US11629195B2 (en) 2023-04-18
KR20210123350A (ko) 2021-10-13
SG11202107272SA (en) 2021-07-29
CN113474370A (zh) 2021-10-01
JP2022519068A (ja) 2022-03-18
EA202192090A1 (ru) 2021-10-20
US20230279131A1 (en) 2023-09-07
CL2021002008A1 (es) 2022-02-04

Similar Documents

Publication Publication Date Title
BR112021014074A2 (pt) Proteínas de ligação ao antígeno anti-receptor il2 gama
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
BR112018067522A2 (pt) anticorpos específicos para receptor de poliovírus humano (pvr)
BR112019010595A2 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto.
MX2021004808A (es) Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos.
MX2020012567A (es) Anticuerpos anti-ox40 y metodos de uso.
BR112020016331A8 (pt) Métodos para tratar câncer com anticorpos anti-pd-1
MX2020010913A (es) Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos.
JOP20210265A1 (ar) الأجسام المضادة لبيروغلوتامات أميلويد بيتا واستخداماتها
MX2021001143A (es) Anticuerpo de union a il-4r humana, fragmento de union a antigeno y uso medico del mismo.
BR112022003956A2 (pt) Anticorpos anti-cd73
WO2019028182A3 (en) TREATMENT OF CANCER USING ANTIBODIES BINDING TO THE HUMAN CD134 RECEPTOR (OX40)
BR112021025077A2 (pt) Anticorpos anti-sortilina para uso em terapia
Sanchorawala et al. Safety and tolerability of daratumumab in patients with relapsed light chain (AL) amyloidosis: preliminary results of a phase II study
CO2021011944A2 (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
PH12020551012A1 (en) Monoclonal antibodies and methods for using same
BR112022006620A2 (pt) Anticorpos contra o receptor de poliovírus (pvr) e seus usos
ECSP21046332A (es) Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano y los métodos para su uso
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
BR112019003307A2 (pt) anticorpo ou seu fragmento de ligação a antígeno, capaz de se conectar a um receptor humano de interleucina-6
ECSP21046333A (es) Anticuerpos humanizados contra la región de la cadena beta de la 9na familia trbv9 del tcr humano y sus métodos de uso
MX2022004058A (es) Kir3dl3 es un receptor inhibidor del sistema inmunitario y usos del mismo.
BR112022003635A2 (pt) Anticorpo anti-vsig4 ou fragmento de ligação ao antígeno e seu uso
MX2022003191A (es) Terapias de combinacion con anticuerpos entpd2 y cd73.